| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid F targets multiple pathways involved in cancer progression and inflammation. It suppresses tumor cell proliferation and induces apoptosis. It modulates inflammatory pathways, partly through inhibition of NF-κB and MAPK signaling. The compound is associated with mechanisms related to angiogenesis inhibition, cell proliferation, cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress. Its diverse targets contribute to its anticancer and immunomodulatory activities.
|
|---|---|
| ln Vitro |
At an IC50 value of 19.5 μM, ganoderic acid F (48 hours) suppresses the growth of HeLa human cervical cancer cells [2].
In vitro, ganoderic acid F suppresses tumor cell proliferation, induces apoptosis, and modulates inflammatory pathways. It inhibits NF-κB and MAPK signaling. The compound has anticancer, hepatoprotective, antioxidant, and immunomodulatory effects. Its activity is typically evaluated using cell viability and proliferation assays in cancer cell lines, as well as assays measuring apoptosis, inflammatory markers, and signaling pathway activation. However, specific IC50 values are not extensively reported in the available literature. |
| ln Vivo |
In vivo, ganoderic acid F has antitumor and antimetastatic activities. It is associated with inhibition of angiogenesis. The compound has been studied for its anticancer, hepatoprotective, and immunomodulatory effects. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile. The compound is a research tool for studying cancer and inflammation.
|
| Enzyme Assay |
Cell-free assays for ganoderic acid F involve evaluating its biochemical properties and activity. Its ability to inhibit NF-κB and MAPK signaling can be assessed using cell-free kinase assays or transcription factor binding assays. The compound's antioxidant activity can be measured using cell-free radical scavenging assays. Its chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry. The compound is typically dissolved in DMSO for assay preparation.
|
| Cell Assay |
In vitro cellular assays for ganoderic acid F typically involve treating cancer cell lines with various concentrations of the compound. Cells are incubated for defined periods (24-72 hours). Cell viability is assessed using MTT, CellTiter-Glo, or other standard assays. Apoptosis is evaluated using Annexin V/PI staining and caspase activity assays. NF-κB and MAPK signaling pathway activation is assessed by western blotting using phospho-specific antibodies. Inflammatory cytokine production is measured by ELISA.
|
| Animal Protocol |
In vivo animal studies for ganoderic acid F are conducted in models of cancer and inflammation. The compound is administered via various routes including oral gavage or intraperitoneal injection. Tumor growth and metastasis are monitored in cancer models. Inflammatory markers are measured in serum and tissues. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating anticancer and anti-inflammatory agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ganoderic acid F include a molecular weight of 570.67 g/mol and molecular formula C32H42O9. It has a density of 1.25±0.1 g/cm3 and solubility of 6.8E-4 g/L in water. As a natural triterpenoid from Ganoderma lucidum, it is expected to have moderate oral bioavailability. The compound is typically stored at appropriate conditions as a research reagent. Detailed ADME parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ganoderic acid F has not been extensively characterized in published literature. As a natural product from Ganoderma lucidum, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Ganoderic acid F is a triterpenoid compound. Ganoderic acid F has been discovered in Ganoderma lucidum, and relevant data have been reported.
Ganoderic acid F is a triterpenoid from Ganoderma lucidum with antitumor and antimetastatic activities. It suppresses tumor cell proliferation, induces apoptosis, and modulates inflammatory pathways via NF-κB and MAPK inhibition. Its molecular formula is C32H42O9 with a molecular weight of 570.67 g/mol. Ganoderic acid F is a research tool for studying cancer, inflammation, and immunomodulation. It is not for therapeutic use. |
| Molecular Formula |
C32H42O9
|
|---|---|
| Molecular Weight |
570.67048
|
| Exact Mass |
570.282
|
| CAS # |
98665-15-7
|
| Related CAS # |
Ganoderic acid F; 98665-15-7
|
| PubChem CID |
23247895
|
| Appearance |
Light yellow to green yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
709.3±60.0 °C at 760 mmHg
|
| Flash Point |
222.9±26.4 °C
|
| Vapour Pressure |
0.0±4.9 mmHg at 25°C
|
| Index of Refraction |
1.553
|
| Source |
Originated from plants: Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst.
Originated from microorganisms |
| LogP |
2.93
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
41
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC(=O)CC(C)C(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1([C@@H](C(=O)C3=C2C(=O)C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)OC(=O)C)C)C
|
| InChi Key |
BWCNWXLKMWWVBT-AIMUVTGPSA-N
|
| InChi Code |
InChI=1S/C32H42O9/c1-15(11-18(34)12-16(2)28(39)40)19-13-23(37)32(8)24-20(35)14-21-29(4,5)22(36)9-10-30(21,6)25(24)26(38)27(31(19,32)7)41-17(3)33/h15-16,19,21,27H,9-14H2,1-8H3,(H,39,40)/t15-,16?,19-,21+,27-,30+,31+,32+/m1/s1
|
| Chemical Name |
(6R)-6-[(5R,10S,12S,13R,14R,17R)-12-acetyloxy-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~175.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7523 mL | 8.7616 mL | 17.5233 mL | |
| 5 mM | 0.3505 mL | 1.7523 mL | 3.5047 mL | |
| 10 mM | 0.1752 mL | 0.8762 mL | 1.7523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
